Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Silence Therapeutics PLC maintains a gross margin of 59.75%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -16505.66%, while the net margin is -13181.13%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively SLN converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, SLN competes directly with industry leaders such as PAYS and FC. With a market capitalization of $224.36M, it holds a significant position in the sector. When comparing efficiency, SLN's gross margin of 59.75% stands against PAYS's 46.12% and FC's 72.74%. Such benchmarking helps identify whether Silence Therapeutics PLC is trading at a premium or discount relative to its financial performance.
